Wisotzkey J D, Bell T, Monk J S
Department of Research, York Hospital, Pennsylvania, USA.
Diagn Mol Pathol. 1998 Jun;7(3):180-3. doi: 10.1097/00019606-199806000-00010.
A novel mutation in the 3' untranslated region of the prothrombin gene, prothrombin 20210A, recently has been identified. This mutation is associated with increased serum prothrombin levels and an increased risk for venous thromboembolism. Patients who carry a mutation in the factor V gene (factor V Leiden) have also been demonstrated to be at increased risk for venous thromboembolism, and previous studies have identified a population prevalence of approximately 5% to 10% for the factor V Leiden allele. To simply and reliably identify patients who carry both genetic defects, a novel assay was developed that simultaneously determines the genotype of patients for the factor V Leiden allele and the prothrombin 20210A mutation. Representative samples (samples positive and negative for each mutation and a "double mutant") were then subjected to this single-tube genotyping assay. The results indicate that the simultaneous genotyping of these mutations will readily characterize the allelic status of patients for the two most frequent genetic mutations in the coagulation cascade.
最近,凝血酶原基因3'非翻译区的一种新型突变——凝血酶原20210A已被发现。这种突变与血清凝血酶原水平升高及静脉血栓栓塞风险增加有关。携带因子V基因(因子V莱顿)突变的患者也被证实静脉血栓栓塞风险增加,先前的研究已确定因子V莱顿等位基因在人群中的患病率约为5%至10%。为了简单可靠地识别同时携带这两种基因缺陷的患者,开发了一种新型检测方法,可同时确定患者因子V莱顿等位基因和凝血酶原20210A突变的基因型。然后将代表性样本(每种突变的阳性和阴性样本以及一个“双突变体”)进行这种单管基因分型检测。结果表明,这些突变的同时基因分型将很容易确定患者在凝血级联反应中两种最常见基因突变的等位基因状态。